Treatment of benign prostatic hyperplasia

Details for Australian Patent Application No. 2004206869 (hide)

Owner Threshold Pharmaceuticals, Inc.

Inventors Tidmarsh, George

Agent Spruson & Ferguson

Pub. Number AU-A-2004206869

PCT Pub. Number WO2004/064735

Priority 60/488,265 18.07.03 US; 60/496,163 18.08.03 US; 60/441,110 17.01.03 US; 60/442,344 23.01.03 US; 60/458,663 28.03.03 US; 60/458,665 28.03.03 US; 60/458,846 28.03.03 US; 60/460,012 02.04.03 US; 60/472,907 22.05.03 US

Filing date 16 January 2004

Wipo publication date 5 August 2004

International Classifications

A61K 031/415 - 1,2-Diazoles

Event Publications

28 July 2005 PCT application entered the National Phase

  PCT publication WO2004/064735 Priority application(s): WO2004/064735

16 August 2007 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004206870-Treatment of benign prostatic hyperplasia using energolytic agents

2004206868-Use of TFF2, or agents inducing TFF2, in the therapy of allergies